Mitochondrial myopathy caused by clevudine therapy in chronic hepatitis B patients

Hepatology Research

Volumn 39, Issue 9, 2009, Pages 944-947

  Tak, Won Young ^a   Park, Soo Young ^a   Jung, Min Kyu ^a   Jeon, Seong Woo ^a   Cho, Chang Min ^a   Kweon, Young Oh ^a   Kim, Sung Kook ^a   Choi, Yong Hwan ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CLEVUDINE; CREATINE KINASE; FRUCTOSE BISPHOSPHATE ALDOLASE; HEPATITIS B(E) ANTIBODY; LACTATE DEHYDROGENASE ISOENZYME; LACTIC ACID; PYRUVIC ACID;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAMNESIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; ELECTRON MICROSCOPY; ELECTROPHORESIS; ENZYME BLOOD LEVEL; FEMALE; HEPATITIS B; HUMAN; HUMAN TISSUE; LACTATE BLOOD LEVEL; LACTATE DEHYDROGENASE BLOOD LEVEL; LIMB WEAKNESS; MALE; MITOCHONDRIAL MYOPATHY; MUSCLE BIOPSY; MUSCLE EXERCISE; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 69949106858     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1872-034X.2009.00515.x     Document Type: Article

References (11)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337: 1733-45.
2. Chu CK, Ma T, Shanmuganathan K etal. Use of 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein-Barr virus. Antimicrob Agents Chemother 1995; 39: 979-81.
3. Marcellin P, Mommeja-Marin H, Sacks SL et al. A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B. Hepatology 2004; 40: 140-8.
4. Yao GQ, Liu SH, Chou E, Kukhanova M, Chu CK, Cheng YC. Inhibition of Epstein-Barr virus replication by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Biochem Pharmacol 1996; 51: 941-7.
5. Balakrishna Pai S, Liu SH, Zhu YL, Chu CK, Cheng YC. Inhibition of hepatitis B virus by a novel L-nucleoside, 2′-fluoro-5-methyl-beta-L-arabinofuranosyl uracil. Antimicrob Agents Chemother 1996; 40: 380-6.
6. Ma T, Pai SB, Zhu YL et al. Structure-activity relationships of 1-(2-Deoxy-2-fluoro-beta-L-arabinofuranosyl) pyrimidine nucleosides as anti-hepatitis B virus agents. J Med Chem 1996; 39: 2835-43.
7. Yoo BC, Kim JH, Chung YH et al. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology 2007; 45: 1172-8.
8. Yoo BC, Kim JH, Kim TH et al. Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression. Hepatology 2007; 46: 1041-8.
9. Cui L, Yoon S, Schinazi RF, Sommadossi JP. Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest 1995; 95: 555-63.
10. McKenzie R, Fried MW, Sallie R et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333: 1099-105.
11. Chu CK, Boudinot FD, Peek SF et al. Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent. Antivir Ther 1998; 3: 113-21.